EXPRS2 — ExpreS2ion Biotech Holding AB Share Price
0.000.00%
Last trade - 00:00- SEK112.58m
- SEK55.25m
- SEK8.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.85 | ||
| Price to Tang. Book | 1.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -168.54% | ||
| Return on Equity | -116.88% | ||
| Operating Margin | -1204.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 13.83 | 15.26 | 13.73 | 6.15 | 8.8 | 10 | 20.5 | -0.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
Directors
- Martin Jensen CHM (56)
- Bent Frandsen CEO
- Charlotte Dyring COO (48)
- Willem de Jongh CSO
- Jakob Knudsen DRC (52)
- Gitte Pedersen DRC (53)
- Allan Rosetzsky DRC (68)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 3rd, 2015
- Public Since
- July 29th, 2016
- No. of Employees
- 28
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 51,404,958
- Address
- Ronnowsgatan 8 C, HELSINGBORG, 25225
- Web
- Phone
- Contact
- Keith Alexander
- Auditors
- Ernst & Young AB
Upcoming Events for EXPRS2
Similar to EXPRS2
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the ExpreS2ion Biotech Holding AB share price?
As of Today at 19:08 UTC, shares in ExpreS2ion Biotech Holding AB are trading at SEK2.19. This share price information is delayed by 15 minutes.
How has the ExpreS2ion Biotech Holding AB share price performed this year?
Shares in ExpreS2ion Biotech Holding AB last closed at SEK2.19 and the price had moved by -64.68% over the past 365 days. In terms of relative price strength the ExpreS2ion Biotech Holding AB share price has underperformed the FTSE Global All Cap Index by -67.42% over the past year.
What are the analyst and broker recommendations for ExpreS2ion Biotech Holding AB?
The overall consensus recommendation for ExpreS2ion Biotech Holding AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ExpreS2ion Biotech Holding AB dividend yield?
ExpreS2ion Biotech Holding AB does not currently pay a dividend.
Does ExpreS2ion Biotech Holding AB pay a dividend?
ExpreS2ion Biotech Holding AB does not currently pay a dividend.
When does ExpreS2ion Biotech Holding AB next pay dividends?
ExpreS2ion Biotech Holding AB does not currently pay a dividend.
How do I buy ExpreS2ion Biotech Holding AB shares?
To buy shares in ExpreS2ion Biotech Holding AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ExpreS2ion Biotech Holding AB?
As of the previous close price of SEK2.19, shares in ExpreS2ion Biotech Holding AB had a market capitalisation of SEK112.58m.
Where are ExpreS2ion Biotech Holding AB shares listed?
Here are the trading details for ExpreS2ion Biotech Holding AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: EXPRS2
What kind of share is ExpreS2ion Biotech Holding AB?
Based on an overall assessment of its quality, value and momentum ExpreS2ion Biotech Holding AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ExpreS2ion Biotech Holding AB share price forecast for 2024?
The analyst consensus target price for shares in ExpreS2ion Biotech Holding AB is SEK3.00. That is 36.99% above the last closing price of SEK2.19.
Analysts covering ExpreS2ion Biotech Holding AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.97 for the next financial year.
What is the trend in the ExpreS2ion Biotech Holding AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ExpreS2ion Biotech Holding AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +111.26%.
As of the last closing price of SEK2.19, shares in ExpreS2ion Biotech Holding AB were trading -10.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ExpreS2ion Biotech Holding AB PE Ratio?
The ExpreS2ion Biotech Holding AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ExpreS2ion Biotech Holding AB?
ExpreS2ion Biotech Holding AB's management team is headed by:
- Martin Jensen - CHM
- Bent Frandsen - CEO
- Charlotte Dyring - COO
- Willem de Jongh - CSO
- Jakob Knudsen - DRC
- Gitte Pedersen - DRC
- Allan Rosetzsky - DRC